TARGETING TARGETED TREATMENT FOR IMMUNE AND NON-IMMUNE KIDNEY DISEASES

Area of Science:

• Nephrology
• Immunology
• Cell Biology

Background:

• Systemic lupus erythematosus (SLE) and focal segmental glomerulosclerosis (FSGS) are kidney diseases characterized by glomerular damage.
• Aberrant T cell function and podocyte injury contribute to lupus nephritis and other glomerular diseases.

Purpose of the Study:

• To investigate the role of calcium calmodulin kinase IV (CaMK IV) in lupus nephritis and other glomerular damage.
• To develop targeted nanoparticle-based drug delivery systems for treating these conditions.

Main Methods:

• Quantification of CaMK IV expression in kidney cells (T cells, podocytes, mesangial cells) from patients and animal models.
• Administration of nanoparticles loaded with a CaMK IV inhibitor, targeted via antibodies to CD4 or nephrin.
• Evaluation of therapeutic efficacy in lupus-prone mice and doxorubicin-induced nephropathy models.

Main Results:

• CaMK IV was found to be increased in T cells, podocytes, and mesangial cells in lupus patients and models, correlating with aberrant T cell function and glomerular damage.
• Nanoparticles delivering a CaMK IV inhibitor, targeted to CD4+ T cells, suppressed autoimmunity and lupus nephritis.
• Nanoparticles targeted to nephrin effectively suppressed nephritis in lupus-prone mice and glomerular damage in doxorubicin-treated mice.

Conclusions:

• CaMK IV plays a critical role in the pathogenesis of lupus nephritis and doxorubicin-induced glomerular damage.
• Targeted nanoparticle delivery of CaMK IV inhibitors offers a promising therapeutic strategy for autoimmune kidney diseases.
• Precision drug delivery holds potential for treating various glomerular pathologies.